Last reviewed · How we verify
Curosurf-Group1
Curosurf-Group1 is a Pulmonary surfactant replacement Small molecule drug developed by Ottawa Hospital Research Institute. It is currently in Phase 3 development for Respiratory distress syndrome in premature infants, Meconium aspiration syndrome.
Curosurf is a natural pulmonary surfactant that replaces deficient surfactant in the lungs to improve gas exchange and reduce surface tension in the alveoli.
Curosurf is a natural pulmonary surfactant that replaces deficient surfactant in the lungs to improve gas exchange and reduce surface tension in the alveoli. Used for Respiratory distress syndrome in premature infants, Meconium aspiration syndrome.
At a glance
| Generic name | Curosurf-Group1 |
|---|---|
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | Pulmonary surfactant replacement |
| Target | Pulmonary surfactant (phospholipid and protein complex) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Neonatology |
| Phase | Phase 3 |
Mechanism of action
Curosurf is derived from porcine lung tissue and contains phospholipids and proteins that mimic endogenous pulmonary surfactant. It is administered intratracheally to restore surfactant function in neonates with respiratory distress syndrome, reducing alveolar collapse and improving lung compliance and oxygenation.
Approved indications
- Respiratory distress syndrome in premature infants
- Meconium aspiration syndrome
Common side effects
- Transient oxygen desaturation
- Bradycardia
- Airway obstruction
- Pulmonary hemorrhage
Key clinical trials
- LISA in the Delivery Room for Extremely Preterm Infants (NA)
- Evaluation of the Efficacy of Surfaktant in Preterm Infants by Lung Ultrasound (NA)
- A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Curosurf-Group1 CI brief — competitive landscape report
- Curosurf-Group1 updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI
Frequently asked questions about Curosurf-Group1
What is Curosurf-Group1?
How does Curosurf-Group1 work?
What is Curosurf-Group1 used for?
Who makes Curosurf-Group1?
What drug class is Curosurf-Group1 in?
What development phase is Curosurf-Group1 in?
What are the side effects of Curosurf-Group1?
What does Curosurf-Group1 target?
Related
- Drug class: All Pulmonary surfactant replacement drugs
- Target: All drugs targeting Pulmonary surfactant (phospholipid and protein complex)
- Manufacturer: Ottawa Hospital Research Institute — full pipeline
- Therapeutic area: All drugs in Respiratory/Neonatology
- Indication: Drugs for Respiratory distress syndrome in premature infants
- Indication: Drugs for Meconium aspiration syndrome
- Compare: Curosurf-Group1 vs similar drugs
- Pricing: Curosurf-Group1 cost, discount & access